Book a Meeting

Non-fucosylated Anti-Human CEACAM5 (Altumomab) Therapeutic Antibody (CAT#: BioBet-168ZP) Datasheet

Target
CEACAM5
Isotype
IgG1
Description
ADCC-enhanced Altumomab is a non-fucosylated anti-CEACAM5 therapeutic biobetter antibody.
Indication
Colorectal cancers
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CEACAM5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CEACAM5
Full Name
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5
Background
This gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. The encoded protein is used as a clinical biomarker for gastrointestinal cancers and may promote tumor development through its role as a cell adhesion molecule. Additionally, the encoded protein may regulate differentiation, apoptosis, and cell polarity. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]
Alternative Names
Labetuzumab; cea-cide; 219649-07-7; hMN14; hMN-14; CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e; meconium antigen 100; DKFZp781M2392;
Gene ID
1048
UniProt ID
P06731
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CEACAM5 include Lung Cancer and Rectum Cancer.
Related Pathways
Its related pathways are Cell surface interactions at the vascular wall and Hematopoietic Stem Cells and Lineage-specific Markers.
Function
Cell surface glycoproteins involved in cell adhesion, intracellular signaling and tumor progression (PubMed:2803308, PubMed:10910050, PubMed:10864933). Cell adhesion molecules that mediate homophilic and heterophilic cells and other carcinogenic embryonic antigens, such as CEACAM6 (PubMed: 2803308). By promoting tumor progression, it plays the role of oncogene; induces colorectal cancer cell resistance to anoikis (PubMed:10910050).
Post-translational modifications
Complex immunoreactive glycoprotein with a MW of 180 kDa comprising 60% carbohydrate.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Altumomab
Host
Mouse
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant mouse monoclonal antibody expressed in CHO binding to human CEACAM5.
Indication
Colorectal cancers

Colorectal cancers

Related Products

Highly Galactosylated Anti-CEACAM5 (Altumomab) Antibody (CAT#: BioBet-GA-168ZP)
Non-fucosylated Anti-Human CEACAM5 (BioBet-167ZP) Therapeutic Antibody (CAT#: BioBet-167ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany